Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Brii expands in infectious via deals with Vir, VBI, WuXi Biologics

December 7, 2018 6:19 PM UTC

Brii Biosciences (Shanghai, China) is broadening its pipeline in HBV and other infectious diseases through a series of new and expanded deals announced Dec. 6, even as CEO Zhi Hong said the company is looking to expand into another therapeutic area.

Brii launched in May with $260 million and three initial partnerships to bring infectious diseases to the forefront of innovation in China: one with the AliHealth healthcare arm of the Alibaba Group Holding Ltd. (NYSE:BABA), another with infectious disease start-up Vir Biotechnology Inc. (San Francisco, Calif.), and a memorandum of understanding with Chinese CROs Wuxi AppTec Co. Ltd. (Shanghai:603259) and WuXi Biologics Inc. (HKSE:2269) (see "Partnering on a Mission")...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article